Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Donna Salzman M.D.
Professor
Close
E-mail
dsalzman@uab.edu
Visualizations
Co-author Network
Map of Science
Co-investigator Network
Donna Salzman M.D.
Professor
Positions
Senior Scientist
,
Experimental Therapeutics
,
O'Neal Comprehensive Cancer Center
Professor (P)
,
Medicine - Hematology & Oncology
,
Department of Medicine
1995 -
Senior Scientist (C)
,
O'Neal Comprehensive Cancer Center
,
School of Medicine
2019 -
Publications
Research
Background
Contact
Publications
Selected Publications
Academic Article
Filter
Year
Title
Altmetric
2021
Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation
.
Bone Marrow Transplantation
.
2021
2020
Total body irradiation and risk of breast cancer after blood or marrow transplantation: A blood or marrow transplantation survivor study report
.
Journal of Clinical Oncology
. 38:2872-2882.
2020
2019
Clinicopathological and molecular characteristics of extramedullary acute myeloid leukaemia
.
Histopathology
. 75:185-192.
2019
2019
Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications
.
Biology of Blood and Marrow Transplantation
. 25:233-238.
2019
2018
Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood
.
JAMA Oncology
. 4.
2018
2018
Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2
.
Leukemia
. 32:2706-2709.
2018
2018
Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant
.
Bone Marrow Transplantation
. 53:1345-1348.
2018
2018
Two cases and a review of graft-versus-host disease and the role of hepatitis C treatment in liver transplant patients
2018
2018
Late mortality after autologous blood or marrow transplantation in childhood: A Blood or Marrow Transplant Survivor Study-2 report
.
Blood
. 131:2720-2729.
2018
2017
Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failure
.
Bone Marrow Transplantation
. 52:157-158.
2017
2016
In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia
.
PLoS ONE
. 11.
2016
2016
Acute myofascitis as a manifestation of chronic graft-versus-host disease
.
Muscle and Nerve
. 53:327-329.
2016
2016
Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features
.
Cancer Causes and Control
. 27:81-91.
2016
2012
How we closed the gap between red blood cell utilization and whole blood collections in our institution
.
Transfusion
. 52:1857-1867.
2012
2012
Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients
.
Supportive Care in Cancer
. 20:1405-1415.
2012
2007
Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation
2007
2006
Prospective endoscopic evaluation for gastrointestinal graft-versus-host disease: Determination of the best diagnostic approach
.
Bone Marrow Transplantation
. 38:371-376.
2006
2006
Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen
.
Biology of Blood and Marrow Transplantation
. 12:770-777.
2006
2006
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up
.
Neuro-Oncology
. 8:183-188.
2006
2004
Adoptive Immunotherapy with Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes for Recurrent, EBV-Positive Hodgkin Disease
.
Cancer
. 100:1892-1901.
2004
2003
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma
.
Journal of Neuro-Oncology
. 65:127-134.
2003
2002
Fungal brain abscess in transplant recipients: Epidemiologic, microbiologic, and clinical features
.
Clinical Transplantation
. 16:419-424.
2002
2002
A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan
.
Biology of Blood and Marrow Transplantation
. 8:619-624.
2002
2001
Fatal sickle cell crisis after granulocyte colony-stimulating factor administration [1]
.
Blood
. 97:3313-3314.
2001
2001
Invasive mold infections in allogeneic bone marrow transplant recipients
.
Clinical Infectious Diseases
. 32:1319-1324.
2001
2000
Adoptive immunotherapy with allogeneic EBV CTL for organ transplant patients with ebv induced lymphoproliferative disease
.
Blood
. 96.
2000
2000
Diagnosis of gastrointestinal graft-versus-host disease
.
American Journal of Gastroenterology
. 95:3034-3038.
2000
2000
A phase I-II trial to examine the toxicity of CMV- and EVB-specific cytotoxic T lymphocytes when used for prophylaxis against EVB and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants
.
Human Gene Therapy
. 11:1453-1463.
2000
2000
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma
.
Neuro-Oncology
. 2:114-119.
2000
1997
Bone marrow transplantation for non-Hodgkin's lymphoma: A review
.
American Journal of the Medical Sciences
. 313:228-235.
1997
1996
Malignancy-associated pulmonary veno-occlusive disease: Report of a case following autologous bone marrow transplantation and review
.
Bone Marrow Transplantation
. 18:755-760.
1996
1995
Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors
.
Bone Marrow Transplantation
. 16:353-358.
1995
1994
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma
.
Journal of Clinical Oncology
. 12:1890-1901.
1994
1993
A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors
.
Investigational New Drugs
. 11:169-179.
1993
1993
Durable complete remission in a patient with refractory mediastinal non-seminomatous germ cell tumor after tandem high-dose chemotherapy and autologous bone marrow transplantation
.
Bone Marrow Transplantation
. 12:541-546.
1993
1993
Immunotoxins for the therapy of graft versus host disease.
.
Cancer Treatment and Research
. 68:133-144.
1993
Research
Principal Investigator On
Private Grant
awarded by
Merck, Sharp, and Dohme (MSD) Research Foundation
2011 - 2016
Private Grant
awarded by
CHIMERIX, INC.
2010 - 2012
Investigator On
BMT CTN 1703/1801 A Randomized, Multicenter Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non Myeloablative / Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation and Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)
awarded by
National Marrow Donor Program
2019 - 2025
Private Grant
awarded by
MILLENNIUM PHARMACEUTICALS, INC.
2020 - 2025
Private Grant
awarded by
AMGEN, INC.^
2020 - 2024
Private Grant
awarded by
SYNDAX PHARMACEUTICALS, INC.
2021 - 2024
ECOG-ACRIN Purchase Service Agreement
awarded by
Eastern Cooperative Oncology Group
2019 - 2024
Private Grant
awarded by
MARKER THERAPEUTICS INC
2021 - 2024
Private Grant
awarded by
ONCOIMMUNE, INC.
2020 - 2023
Private Grant
awarded by
MUNDIPHARMA
2018 - 2023
Private Grant
awarded by
BLUEBIRD BIO INC.
2020 - 2023
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507
awarded by
National Marrow Donor Program
2017 - 2023
Private Grant
awarded by
SYNDAX PHARMACEUTICALS, INC.
2019 - 2022
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
awarded by
National Marrow Donor Program
2017 - 2022
IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib
awarded by
VANDERBILT UNIVERSITY
2017 - 2022
Private Grant
awarded by
FATE THERAPEUTICS, INC.
2017 - 2021
A Randomized Phase III Study Comparing Conventional Dose Treatment using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)
awarded by
Dana-Farber Cancer Institute
2013 - 2021
Private Grant
awarded by
ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
2018 - 2021
High VS. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
awarded by
VANDERBILT UNIVERSITY
2017 - 2021
Private Grant
awarded by
ONYX PHARMACEUTICALS, INC.
2015 - 2020
ECOG-ACRIN Purchase Service Agreement
awarded by
Eastern Cooperative Oncology Group
2014 - 2020
BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
awarded by
National Marrow Donor Program
2017 - 2019
Private Grant
awarded by
FATE THERAPEUTICS, INC.
2016 - 2018
Private Grant
awarded by
AASTROM BIOSCIENCES, INC.
2013 - 2018
Private Grant
awarded by
ASTELLAS PHARMA US, INC.
2014 - 2018
Multi-center, Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) Regimen
awarded by
University of Michigan
2012 - 2016
A Genome-Wide Methylation Study of Epigenetic Contributions to Multiple Myeloma
awarded by
National Cancer Institute/NIH/DHHS
2011 - 2015
Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease
awarded by
Emory University
2014 - 2015
Background
Education And Training
Doctor of Medicine,
Louisiana State University System : University of New Orleans
1986
Charity Hospital of New Orleans, Internship
1987
Charity Hospital of New Orleans, Residency
1989
University of Texas Health Science Center, Postdoctoral Fellowship
1993
Charity Hospital of New Orleans, Postdoctoral Fellowship
1990
Contact
Full Name
Donna
Salzman